Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Assets (2016 - 2025)

Historic Current Assets for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $44.1 million.

  • Sangamo Therapeutics' Current Assets fell 2417.81% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.1 million, marking a year-over-year decrease of 2417.81%. This contributed to the annual value of $51.7 million for FY2024, which is 4520.08% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Current Assets of $44.1 million as of Q3 2025, which was down 2417.81% from $49.9 million recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Current Assets high stood at $606.9 million for Q1 2021, and its period low was $37.6 million during Q1 2025.
  • For the 5-year period, Sangamo Therapeutics' Current Assets averaged around $226.6 million, with its median value being $159.6 million (2023).
  • Per our database at Business Quant, Sangamo Therapeutics' Current Assets surged by 6361.97% in 2021 and then plummeted by 7489.18% in 2024.
  • Sangamo Therapeutics' Current Assets (Quarter) stood at $398.8 million in 2021, then dropped by 24.69% to $300.3 million in 2022, then plummeted by 68.59% to $94.3 million in 2023, then crashed by 45.2% to $51.7 million in 2024, then decreased by 14.73% to $44.1 million in 2025.
  • Its last three reported values are $44.1 million in Q3 2025, $49.9 million for Q2 2025, and $37.6 million during Q1 2025.